Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Tiziana Life Sciences Ltd
(NQ:
TLSA
)
1.210
+0.030 (+2.54%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Tiziana Life Sciences Ltd
< Previous
1
2
3
Next >
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
October 11, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
September 26, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences' Alzheimer's treatment validated in new study
September 12, 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company...
Via
TheNewswire.com
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
September 08, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
September 06, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
August 23, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
August 23, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
August 17, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatment
August 15, 2023
Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after announcing that Tiziana has received FDA clearance...
Via
TheNewswire.com
Exposures
Product Safety
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
August 15, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
July 21, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer
June 13, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
June 05, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
May 25, 2023
Webinar to take place on Monday, June 5, 2023 at 12:30 PM ET
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform
May 23, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17
May 17, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst
May 05, 2023
Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new research note on clinical-stage biopharmaceutical company Tiziana Life Sciences Ltd (NASDAQ:TLSA). Tiziana has...
Via
TheNewswire.com
Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
April 27, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update
April 26, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
April 24, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
April 20, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
April 18, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences’ (NASDAQ:TLSA) First-in-Class Foralumab Is Showing Promise
April 17, 2023
Via
ACCESSWIRE
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
April 13, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
NIO Could Bring A Pleasant Beat This Coming Quarter
April 10, 2023
Tesla's price cuts have initiated a full on war across the EV industry, however NIO has refused to follow along. This may present even more upside for the stock
Via
MarketBeat
Topics
Electric Vehicles
Exposures
Electric Vehicles
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai
April 10, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
April 04, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
April 04, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in
March 31, 2023
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
March 28, 2023
FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMS
From
Tiziana Life Sciences Ltd.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.